Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 17/20 | 0.69 |
| ▸ | GABRB3 | P28472 | 17/20 | 0.69 |
| ▸ | GABRA5 | P31644 | 17/20 | 0.69 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.69 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.69 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.69 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.69 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.69 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | GABRP | O00591 | 1/20 | 0.69 |
| ▸ | GABRD | O14764 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | GABRE | P78334 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30661077 | 1.00 | GABRG2 (0.69) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL6870825 | 0.90 | GABRG2 (0.63) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL9261970 | 0.89 | GABRG2 (0.65) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL6867089 | 0.89 | GABRG2 (0.70) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL18329262 | 0.88 | GABRG2 (0.69) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL29618010 | 0.88 | GABRG2 (0.69) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL6873122 | 0.87 | GABRG2 (0.65) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL6866680 | 0.86 | GABRG2 (0.54) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL9260791 | 0.85 | GABRG2 (0.67) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL9269910 | 0.84 | GABRG2 (0.47) | GABRG2GABRB3GABRA5GABRA2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3017016-A | — | — | None | — | — | JP | disclosed |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2023225369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY | DUKE UNIVERSITY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3083569-B1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO INC (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11142529-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210253588-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210009602-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2021-01-14 | — | — | US | disclosed |
| US-4363762-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-12-14 | — | — | US | disclosed |
| US-4359420-A | HYPOTENSIVE AGENT, MUSCLE RELAXANTS | HOFFMANN-LA ROCHE INC. (US) | 1982-11-16 | — | — | US | disclosed |
| US-4346032-A | ANTIDOTES TO OVERDOSES OF BENZODIAZEPINE TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346034-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346031-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346030-A | ANTIDOTES FOR OVERDOSES OF BENZODIAZEPINE TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346036-A | ALKYLATION; AMIDATION; TRANQUILIZER ANTAGONIST | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346035-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346033-A | Thienodiazepinone and benzodiazepinone intermediates | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4316839-A | Imidazodiazepine derivatives | HOFFMAN-LA ROCHE INC. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009602-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | GABRG2 22/4885GABRB3 16/4885GABRA5 2/4885 |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | GABRG2 24/4885GABRB3 15/4885GABRA5 2/4885 |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | GABRG2 22/4885GABRB3 16/4885GABRA5 2/4885 |
| US-11142529-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GRM1 | GABRG2 25/4885GABRB3 17/4885GABRA5 2/4885 |
| US-20210253588-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | GABRG2 19/4885GABRB3 13/4885GABRA5 2/4885 |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | GABRG2 20/4885GABRB3 15/4885GABRA5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.